
The launch of TrumpRx reflects a big change in US medicines policy with global impacts. US policy is now also a tool of trade leverage and geopolitical bargaining, as well as a domestic question - as Washington pushes for lower prices at home and greater international sharing of the R&D costs of innovative medicines.
Against a backdrop of rising geopolitical tension and countries’ renewed focus on domestic capability and economic security, the pharmaceutical sector is moving from technocratic health economics to overt geoeconomic contestation. Alongside tariff threats, security tools once considered exceptional, like export controls, FDI screening, and data restrictions, can become quickly normalised. In a highly globalised industry built on complex supply chains and cross-border R&D, these shifts create significant risks as well as selective opportunities.
In the UK, recent changes to NICE thresholds and a repayment cap illustrate how US interventions are shaping medicines policy as much as domestic industrial strategy. The new settlement is positive progress for the sector. But it is not yet a determined change in direction. As well as preparing for the risks a more complex world presents, firms operating in the UK must continue to make the case for the return on investment their medicines offer.
This month has seen the launch of TrumpRx – the US Government’s new direct-to-consumer platform with the stated aim of delivering ‘most favoured nation’ drug prices to the US after decades in which Americans paid much more for its medicines than most of the rest of the world. US drug pricing continues to be a major domestic political and cost of living issue.
More significant than the initial product range, which majors on GLP-1 weight-loss treatments, is the mechanism: Washington is signalling that US medicine pricing will no longer be treated as a purely domestic reimbursement question, but as a matter of trade leverage and geopolitical bargaining.
The US government is seeking lower prices domestically and greater burden-sharing internationally (so that prices in developed countries do more to support high R&D costs for innovative medicines, rather than relying on much higher US pricing to support this), threatening tariffs against countries and firms that don’t play ball.
In a world of global reference pricing, unilateral US action could also generate second-order effects across reimbursement systems. Pricing frameworks are often interlinked, meaning significant shifts in one major market may place pressure on others that reference comparable benchmarks. Similar pressures are visible across Europe and parts of Asia, where governments are reassessing pricing frameworks, supply chain resilience and domestic manufacturing incentives in light of shifting US policy.
Against a backdrop of rising geopolitical tension and a renewed focus on domestic capability and economic security, the pharmaceutical sector is moving from technocratic health economics to overt geoeconomic contestation. In a highly globalised industry built on complex supply chains and cross-border R&D, this shift creates significant risks as well as selective opportunities.
The threat of US Section 232 tariffs on pharmaceuticals, first raised in April 2025, overturned the decades-old norm that medicines were, implicitly, a public good that should not be tariffed.
But the conditions for more restrictive trade flows have been building for years. COVID demonstrated that where medicines are developed and manufactured can prove consequential when demand outstrips supply or trade routes are disrupted.
For countries that felt left behind in the rush for vaccines and therapeutics, belief in the values of the intellectual property regimes underpinning pharmaceutical innovation further frayed.
With international institutions like the WTO and WHO weaker than ever, the multilateral order can no longer be taken for granted. The result is not simply more friction, but a reframing of medicines as strategic industrial assets, subject to similar resilience, security and leverage logic now being applied to semiconductors, batteries and critical minerals.
Economic security has therefore become a defining feature of medicines policy. The US’s BIOSECURE Act, restricting Federal procurement from certain biotech firms on national security grounds, is one example.
In this environment, firms must assume that tools once considered exceptional, such as export controls, FDI screening, cross-border data restrictions, merger restrictions, and tariffs can be normalised quickly. Strategic competition between the US and China, with the EU increasingly deploying similar instruments, is setting the parameters within which others must operate.
These dynamics are particularly salient in mid-sized advanced economies such as the UK, which has historically benefited from open trade and strong global rules. As a priority sector under the UK Government’s Industrial Strategy, a sector plan in July 2025 promised support for R&D, faster clinical trials, better use of NHS data and grant support for innovative manufacturing.
However, in recent months it has been US trade interventions, rather than domestic industrial strategy, that have most directly shaped UK medicines policy.
The increase in NICE’s cost-effectiveness threshold by £5,000 to £25,000-£35,000 per Quality-Adjusted Life Year and the cap on repayment rates at 15% have been broadly welcomed by industry. Yet these changes were not the product of a settled domestic consensus that higher medicines spending is an investment in growth. Rather, they emerged in the context of wider UK-US trade discussions.
The UK Treasury’s core view – that medicines spending represents an NHS cost that should be minimised rather than an industrial or health investment – has not fundamentally shifted.
The current settlement therefore rests on geopolitical pragmatism rather than ideological alignment. That distinction matters. What some in the sector might hope will prove the first step in a pro-growth realignment is regarded in parts of the UK government as a necessary concession made in the context of wider trade discussions.
That makes the arrangement structurally fragile. US leverage may have unlocked movement in the short term, but it does not resolve the underlying divergence in how the British state and industry conceptualise medicines spending.
These shifts represent a durable change from the pre-COVID era. The assumption that medicines would remain insulated from tariff threats, industrial conditionality and security screening no longer holds.
Flint can support you in navigating pharmaceutical policy as trade and geopolitical dynamics reshape the sector, and in presenting compelling, evidence-based arguments to government. To discuss your particular position with our sector and policy specialists, contact us here.
Authors: Sam Lowe, Katie Whitting, James Hedgeland
Enjoyed this blog? Sign up for our Health Headliners newsletter for analysis of the political and policy developments shaping life sciences, medtech and the healthcare investment environment across the UK and beyond.